Who can get Wegovy tablets in the UK? Eligibility explained

# Who can get Wegovy tablets in the UK? Eligibility explained

Oral Wegovy (semaglutide tablets) received MHRA approval on 11 June 2026, making it the first oral GLP-1 weight management medicine available in the UK. The question many people are now asking is simple: do I qualify?

The answer depends on your BMI, your health history, and whether any medical factors would make the treatment unsuitable for you. This guide explains the full eligibility framework — who meets the criteria, who does not, and what the assessment process actually involves when you approach a UK provider.

> **Important:** Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. The criteria below are general guidance — your individual suitability must be assessed by a registered prescriber.

—

## The core BMI criteria

The starting point for eligibility is body mass index (BMI). UK private providers are broadly applying criteria consistent with those used in the OASIS 2 clinical trial and in line with existing semaglutide prescribing guidance:

**BMI 30 or above:** You meet the primary weight threshold for consideration as a Wegovy tablet candidate. This applies regardless of whether you have any other health conditions.

**BMI 27–29.9 with at least one weight-related health condition:** You may also be eligible if your BMI falls in this range but you have one or more relevant comorbidities. These conditions include:
– Type 2 diabetes
– High blood pressure (hypertension)
– High cholesterol (dyslipidaemia)
– Obstructive sleep apnoea
– Cardiovascular disease (including history of heart attack or stroke)
– Non-alcoholic fatty liver disease

The rationale for including people with a BMI between 27 and 30 is well established in clinical literature: weight-related health conditions often emerge before a person reaches a BMI of 30, and treatment can deliver cardiovascular and metabolic benefit even when the absolute BMI threshold is not met.

BMI is calculated from your weight in kilograms divided by the square of your height in metres. Most online providers will ask you to enter your weight and height and calculate it for you.

—

## Age requirements

You must be 18 or over to be prescribed Wegovy tablets in the UK. The medicine is not licensed for use in under-18s.

At the other end of the age range, most providers assess patients up to 74 years old as a routine matter. Patients aged 75 and above are not automatically excluded, but a more detailed individual clinical assessment is typically required, as older patients may be more susceptible to certain side effects and may have a more complex medication background. If you are in this age group, a prescriber who takes the time to review your full health history properly is essential.

—

## Who cannot take Wegovy tablets

There are several absolute contraindications — medical reasons why Wegovy tablets must not be prescribed regardless of BMI or health goals.

### Personal or family history of medullary thyroid carcinoma (MTC)

Semaglutide has been shown in animal studies to increase the risk of thyroid C-cell tumours. While the relevance to humans is uncertain, prescribers are required to exclude patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), which is associated with MTC. If you have either of these in your personal or family medical history, you cannot be prescribed Wegovy tablets.

### Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Linked to MTC risk as above. Patients with confirmed or suspected MEN2 are not eligible.

### Pregnancy or breastfeeding

Wegovy tablets must not be used during pregnancy. Semaglutide has the potential to cause foetal harm. Women of childbearing age are advised to use effective contraception while taking Wegovy tablets. If you become pregnant while on treatment, you should stop immediately and inform your prescriber. Breastfeeding women are also excluded, as it is unknown whether semaglutide passes into breast milk.

### Type 1 diabetes

Wegovy tablets are not approved for use in type 1 diabetes. The medicine is not indicated for blood glucose management in type 1 — it is approved for weight management in adults with obesity or overweight with comorbidities, and this indication does not extend to type 1 diabetes. Patients with type 1 should not be prescribed this treatment.

### Severe kidney disease

Patients with severely impaired kidney function (eGFR below 15 ml/min/1.73m², classified as kidney failure or stage 5 chronic kidney disease) are not eligible. Kidney function is relevant to how the body processes semaglutide and its metabolites.

### Severe liver disease

Patients with severe hepatic impairment are excluded. Prescribers will ask about liver conditions as part of the standard assessment.

### Known hypersensitivity to semaglutide

If you have previously had an allergic reaction to semaglutide or any ingredient in the tablet formulation, you cannot be prescribed Wegovy tablets. This is rare but is an absolute contraindication.

—

## Conditions requiring careful assessment

Some medical situations do not automatically disqualify you but require more detailed clinical assessment and, in some cases, enhanced monitoring.

### Type 2 diabetes

Patients with type 2 diabetes can take Wegovy tablets, but there are important considerations. Semaglutide lowers blood glucose as well as supporting weight loss. If you are already on insulin or a sulphonylurea (such as gliclazide or glipizide), adding semaglutide significantly increases the risk of hypoglycaemia (low blood sugar). Dose adjustments to your diabetes medicines may be necessary, and your prescriber needs to be aware of your full diabetes treatment plan before prescribing.

### History of pancreatitis

There is an association between GLP-1 receptor agonists and pancreatitis, though causality has not been definitively established. If you have a history of acute or chronic pancreatitis, your prescriber will weigh this carefully and may decline to prescribe or may require specialist review.

### History of eating disorders

A history of anorexia nervosa, bulimia nervosa, or other eating disorders requires careful clinical consideration. GLP-1 medicines have powerful appetite-suppressing effects. Prescribing in this context requires a thorough assessment and ongoing monitoring. Most responsible UK providers will require you to disclose any eating disorder history and will assess accordingly.

### Diabetic retinopathy

Some clinical data suggests semaglutide treatment can temporarily worsen diabetic retinopathy — a diabetic eye condition — particularly in patients who experience rapid blood glucose improvement. Patients with known diabetic retinopathy should discuss this with their prescriber and ensure appropriate ophthalmology monitoring is in place.

—

## The assessment process: what to expect

UK providers offering Wegovy tablets privately conduct their assessments online, typically via a structured questionnaire followed by prescriber review. Here is what a thorough assessment covers.

**Weight and height:** To calculate BMI. Some providers ask for a recent weight (within the past few weeks) rather than accepting estimates.

**Medical history:** A systematic review of current and past health conditions, including all conditions listed as contraindications or cautions above. Providers should ask specifically about thyroid conditions, diabetes, pancreatitis, cardiovascular disease, and kidney function.

**Current medications:** A full medicines review is essential. Semaglutide can interact with other medicines — particularly those for diabetes — and a prescriber needs a complete picture before issuing a prescription.

**Blood pressure:** Most online providers ask for a recent blood pressure reading. Some request this as a self-measured reading; others may ask for a GP or pharmacy measurement within the past three months.

**Mental health and eating history:** Responsible providers include questions about mental health and eating disorder history. Declining to answer or omitting this information can affect treatment safety.

**Assessment turnaround:** Most online providers aim to complete the clinical review within 24–48 hours. Some offer same-day assessment. The speed of assessment varies by provider and demand.

—

## Private assessment vs NHS referral

**Private route:** A GP referral is not required to access Wegovy tablets privately. You can approach a registered UK provider directly, complete their online assessment, and — if eligible — receive a prescription. The assessment is carried out by a prescribing clinician employed by or contracted to the provider.

**NHS route:** As of June 2026, Wegovy tablets (oral semaglutide) are not available on the NHS. NHS access to semaglutide for weight management currently applies only to injectable forms, and only via specialist weight management services with significantly higher BMI thresholds (typically BMI 40 or above). Anyone seeking Wegovy tablets must go through a private provider.

It is worth noting that even if you do not meet NHS criteria or cannot access a specialist service, you may still meet the private prescribing criteria described above. The private threshold (BMI 30, or 27 with comorbidity) is considerably lower than the NHS specialist service threshold.

—

## If you do not meet the criteria

A responsible prescriber will decline to prescribe if you do not meet the eligibility criteria and explain the reason. This is a patient safety matter, not an administrative inconvenience.

Be cautious of any provider who offers to prescribe Wegovy tablets without conducting a thorough assessment, without asking about medical history, or without checking for contraindications. Prescribing without proper clinical assessment puts patients at risk and is not consistent with UK regulatory standards.

If you have been declined and want to understand why, your prescribing clinician should be able to explain the clinical reasoning. In some cases, there may be alternative options worth discussing with your GP.

—

## Frequently asked questions

### What BMI do I need for Wegovy tablets in the UK?

You need a BMI of 30 or above, or a BMI of 27–29.9 with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, or cardiovascular disease. BMI alone is not the only factor — contraindications and your full medical history are also assessed.

### Can I get Wegovy tablets if I have type 2 diabetes?

Yes, in most cases — but it requires careful assessment. If you are already on insulin or a sulphonylurea, there is an increased risk of low blood sugar, and your diabetes medicines may need adjustment. Your prescriber needs to know your full diabetes treatment plan before prescribing Wegovy tablets.

### Do I need a GP referral to get Wegovy tablets privately?

No. You can approach a registered UK provider directly and complete their online assessment without a GP referral. A clinician employed by the provider will review your assessment and issue a prescription if you are eligible. However, it is good practice to inform your GP that you are starting treatment.

### Are Wegovy tablets available on the NHS?

As of June 2026, no. Oral semaglutide (Wegovy tablets) is not available on the NHS. NHS access to semaglutide for weight management currently applies only to injectable forms, via specialist services with BMI thresholds typically above 40. Private prescription is the only current route.

### What stops someone from getting Wegovy tablets?

Absolute contraindications include a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, pregnancy or breastfeeding, type 1 diabetes, severe kidney disease, severe liver disease, and known allergy to semaglutide. Being under 18 is also an absolute exclusion.

### How long does an online eligibility assessment take?

Most UK online providers aim to complete clinical review within 24–48 hours of submission. Some offer same-day assessment for straightforward applications. The time can vary depending on provider demand and whether the prescriber requires additional information.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting or changing treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*